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ABSTRACT
◥
Purpose: This randomized, multicenter, open-label, phase Ib/II
study assessed durvalumab and tremelimumab in combination
or as monotherapy for chemotherapy-refractory gastric cancer or
gastroesophageal junction (GEJ) cancer.
Patients and Methods: Second-line patients were random-
ized 2:2:1 to receive durvalumab plus tremelimumab (arm
A), or durvalumab (arm B) or tremelimumab monotherapy
(arm C), and third-line patients received durvalumab plus
tremelimumab (arm D). A tumor-based IFNg gene signature
was prospectively evaluated as a potential predictive bio-
marker in second- and third-line patients receiving the
combination (arm E). The coprimary endpoints were objec-
tive response rate and progression-free survival (PFS) rate at
6 months.
Results: A total of 113 patients were treated: 6 in phase Ib and
107 (arm A, 27; arm B, 24; arm C, 12; arm D, 25; arm E, 19) in
phase II. Overall response rates were 7.4%, 0%, 8.3%, 4.0%, and
15.8% in the five arms, respectively. PFS rates at 6 months were
6.1%, 0%, 20%, 15%, and 0%, and 12-month overall survival
rates were 37.0%, 4.6%, 22.9%, 38.8%, and NA, respectively.
Treatment-related grade 3/4 adverse events were reported in
17%, 4%, 42%, 16%, and 11% of patients, respectively.
Conclusions: Response rates were low regardless of mono-
therapy or combination strategies. No new safety signals were
identified. Including use of a tumor-based IFNg signature and
change in baseline and on-treatment circulating tumor DNA are
clinically feasible and may be novel strategies to improve treat-
ment response in this difficult-to-treat population.
Introduction
Responses to approved treatments in the first- and second-line
metastatic gastric cancer and gastroesophageal junction (GEJ) cancer
settings are short lived, with virtually all patients experiencing disease
progression (1, 2). For patients receiving two or more lines of treat-
ment, options are limited, and treatment regimens involving novel
approaches are urgently needed (3). Increasing understanding of
tumor immunity and gastric cancer/GEJ cancer pathogenesis has
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fueled investigations of immune checkpoint inhibitors (ICI) in the
setting of chemotherapy-refractory advanced or metastatic gastric
cancer/GEJ cancer. Trials of anti–PD-1 and anti–CTL protein 4
(CTLA-4) ICIs (4–9), including pembrolizumab (5, 9) and nivolu-
mab (7) as monotherapy and nivolumab in combination with ipili-
mumab, have shown durable clinical responses with acceptable tox-
icity profiles (6).
Although the antitumor effect and long-term durability observed
in responders treated with ICI monotherapy and combination
therapy are encouraging, the identification of novel predictive
biomarkers to predict response is paramount. Approximately
40% of patients with gastric cancer/GEJ cancer express PD-L1 on
tumor and immune cells (5, 10). In addition, microsatellite insta-
bility status (MSI) is associated with an improved prognosis as well
as a reduced risk of lymph node metastasis, tumor invasion, and
mortality (11, 12).
Interferon-gamma (IFNg) produced by activated T cells and natural
killer cells can directly upregulate PD-L1 expression and promote
cytotoxicity through tumor-infiltrating macrophages recruitment,
cytotoxic T-cell proliferation, and nitric oxide production. T-cell
inflamed tumors show a high IFNg signature (13). An IFNg gene
signature associated with improved response to pembrolizumab in
multiple tumor indications, including gastric cancer/GEJ cancer has
been identified (14). Similarly, patients with non–small-cell lung
cancer receiving durvalumab with high expression of a four-gene
signature comprising IFNg, CD274, LAG3, and CXCL9 had higher
overall response rates, longer progression-free survival (PFS), and
improved overall survival (OS) than those with low expression, and
these findings were replicated in an independent urothelial cancer
cohort (15). Given the moderate-to-high expression of IFNg signature
in a subset of gastric cancer/GEJ tumors, we performed a prospective
evaluation of patients based on signature status.
The anti–PD-L1 antibody durvalumab has demonstrated durable
clinical activity and a manageable safety profile in multiple tumor
types, including gastric cancer/GEJ cancer (16–19). In addition, the
anti–CTLA-4 antibody tremelimumab has the potential to interrupt a
key coinhibitory signal, thus leading to T-cell activation in advanced
gastric cancer/GEJ cancer (10, 20). In this study, we investigated the
potential clinical benefits of durvalumab and tremelimumab in com-
bination and as monotherapy in chemotherapy-refractory advanced
gastric cancer/GEJ cancer. We also prospectively evaluated the ability
of a tumor-based IFNg gene signature to identify a subset of second-
and third-line patients with gastric cancer/GEJ cancer who were most
likely to respond to dual ICI therapy.
Patients and Methods
Study design and treatments
This study is registered withClinicalTrials.gov (NCT02340975) and
was conducted at 30 centers globally, including sites in Canada (2),
Japan (3), Korea (4), Singapore (2), Taiwan (3), and the United
States (16), from March 2015 to January 2018. The study protocol
and amendments were approved by local institutional boards and
performed in accordance with the Declaration of Helsinki and is
consistent with International Conference on Harmonisation, Good
Clinical Practice, and applicable regulatory requirements. All patients
provided written informed consent.
The phase Ib portion of the study (N ¼ 6) involved a safety run-in
assessment of durvalumab and tremelimumab at doses and schedules
selected for dose expansion in patients with gastric or GEJ adenocar-
cinoma. Patients received durvalumab 20 mg/kg plus tremelimumab
1 mg/kg i.v. every 4 weeks (Q4W) for four cycles, followed by
durvalumab 10 mg/kg every 2 weeks (Q2W) for up to 12 months (16).
Patients were monitored for dose-limiting toxicities before enrollment
in phase II (Supplementary Fig. S1).
In the phase II portion (N ¼ 88), 63 patients with disease
refractory to one platinum- or fluoropyrimidine-based chemother-
apy regimen were randomized 2:2:1 to one of three second-line
treatment arms: A, B, or C. Third-line patients who had progressed
on two regimens enrolled in arm D (n ¼ 25). Patients in all arms
were treated for up to 12 months. Patients in arms A and D received
durvalumab 20 mg/kg plus tremelimumab 1 mg/kg Q4W for four
cycles, followed by durvalumab 10 mg/kg Q2W. Patients in arm B
received durvalumab monotherapy (10 mg/kg) Q2W. Patients in
arm C received tremelimumab monotherapy (10 mg/kg) Q4W for
seven doses and then every 12 weeks for two doses (for a total of up
to 9 doses). Patients in the durvalumab and tremelimumab mono-
therapy arms could cross over to combination therapy at the time of
disease progression if they met specific criteria. Those who did not
have progression during the first 12 months and entered follow-up
were eligible for retreatment for up to 12 months at the time of
progression.
An additional arm (arm E; n ¼ 19) was added per a study
amendment to prospectively evaluate the ability of a tumor-based
IFNg gene signature in second- and third-line patients to identify
patients with an increased likelihood of response. Prescreening was
undertaken using archival formalin-fixed paraffin-embedded tissue to
assign IFNg signature status with a custom, targeted RNA sequencing
assay using Ion AmpliSeq (Thermo Fisher Scientific) sequencing
technologies. The positive cutoff was established at the upper tertile
of IFNg expression from an existing dataset, including data from arms
A–D (15). Patients whowere positive were eligible to be screened upon
progression while receiving first- or second-line therapy. Patients
enrolled in this arm received durvalumab 20 mg/kg and tremelimu-
mab 1 mg/kg i.v. Q4W for four cycles, followed by durvalumab
10 mg/kg Q2W for 12 months.
A prespecified interim analysis was performed on arms A and B
after 20 patients were enrolled and followed for 8 weeks to assess
whether the criterion for expansion [2 of 20 patients with complete
response (CR), partial response (PR), or stable disease (SD) for 8weeks]
was met. If the criterion was not met, enrollment in arms A, B, and C
could be stopped. Preliminary biomarker data could be used to support
the decision to continue or stop enrollment. Similar interim analyses
were planned for arm D (enrollment could stop if 2 of 25 patients
had CR or PR) and arm E (enrollment could stop if 3 of 20 patients
had CR or PR).
Translational Relevance
In this randomized, multicenter phase 1b/II clinical study
of metastatic/recurrent gastric or gastroesophageal junction cancer
(n ¼ 113), durvalumab plus tremelimumab demonstrated low
response rates, a 12-month overall survival (OS) rate similar to
that reported previously for checkpoint inhibitor combination, and
a tolerable safety profile. Prospectively screening patients using a
novel RNA-based IFNg signature from archival tissue was feasible,
but this patient selection did not improve clinical response.
Changes in circulating tumor DNA variant allele frequency cor-
related with median progression-free survival and OS, suggesting
utility as an early indicator of clinical benefit.
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Patients
Key inclusion criteria included histologic or cytologic confirmation
of metastatic or recurrent gastric or GEJ adenocarcinoma that pro-
gressed after2 lines of systemic platinum- orfluoropyrimidine-based
chemotherapy and presence of a measurable lesion amenable to
biopsy. Key exclusion criteria included HER2-overexpressing
metastatic or recurrent gastric cancer/GEJ cancer; active or prior
documented autoimmune or inflammatory disease within 3 years;
and prior treatment with any immunotherapy.
Study assessments
The coprimary efficacy endpoints for the phase II portion were the
confirmed objective response rate (ORR) and PFS at 6months (PFS-6)
based on investigator assessment according to Response Evaluation
Criteria in Solid Tumors (RECIST) version 1.1. Clinical activity was
assessed by imaging every 8 weeks through end of treatment.
Secondary endpoints included the safety of durvalumab and tre-
melimumab in combination, durvalumab monotherapy, and treme-
limumab monotherapy, including adverse events (AE) and serious
AEs based on laboratory parameters, vital signs, and electrocardio-
grams. AEs were assessed and graded using the National Cancer
Institute Common Terminology Criteria for AEs, version 4.0 (21).
Clinical activity of durvalumab and tremelimumab in combination
and as monotherapy was further assessed by disease control rate,
duration of response, PFS, and OS.
PD-L1 expression was determined by IHC [Ventana PD-L1
(SP263) assay] and analyzed for correlation with clinical activity
of durvalumab and tremelimumab. PD-L1 expression was deter-
mined to be positive if the proportion of tumor cells with staining at
any intensity was 1%.
Prognostic scores
Prognostic scores were retrospectively calculated to characterize the
baseline features of the different treatment arms in phase II and allow
retrospective analysis. These scores included the Royal Marsden
Hospital (RMH) prognostic score (22) and the Gustave-Roussy
Immune (GRIm)-score (23). The RMH score is based on three
objective variables: number of metastatic sites (<3 or3 sites), lactate
dehydrogenase level [less than the upper limit of normal (ULN) or
greater than or equal to the ULN], and serum albumin level (<3.5 or
3.5 g/dL). For each variable, the score was validated in patients
treatedwith cytotoxic and targeted therapies (22). Patientswith a lower
RMH score at baseline (0 or 1) had a longer median OS than patients
with a poor prognostic score (2 or 3). The GRIm score is based on
serum albumin level, lactate dehydrogenase level, and neutrophil-to-
lymphocyte ratio. Patients with a high GRIm score (>1) had inferior
OS compared with those with a lower score (0 or 1). This has been
prospectively validated for patients in phase 1 trials receiving
immunotherapy (23).
Circulating tumor DNA
A 73-gene panel measured DNA variants using the Guardant360
assay in plasma circulating tumor DNA (ctDNA). Treatment arms
were combined to demonstrate associations of changes in mutation
variant allele frequencies (VAF) with clinical response. Mutation
VAFs and total mutation count of patient single-nucleotide variants
and insertions/deletions were correlated with clinical outcomes.
ORR was calculated according to RECIST 1.1. Cox proportional
HRs were calculated while adjusting for age, sex, Eastern Cooper-
ative Oncology Group performance status, line of therapy, and
treatment arm.
Statistical analyses
All analyses were performed for the as-treated population, which
included patients who received one or more dose of any study drug.
The coprimary efficacy endpoints of ORR and PFS-6 were based on
RECIST 1.1. For ORR, the two-sided 95% exact confidence intervals
(CI) were estimated using binomial distribution. For PFS-6, Kaplan–
Meier estimates were provided along with two-sided 95% CIs. Sample
size determination was based primarily on providing sufficient pre-
cision for estimating ORR and PFS-6. The targeted ORR range was
approximately 35%; with full enrollment the study would have had
85% power to detect a difference in ORR of 35% in arm A and 10% in
arm B. The targeted PFS-6 rate was 53%, corresponding to a median
PFS of 6.6 months or a 50% improvement over the median PFS
reported for ramucirumab þ paclitaxel (24).
Results
At the data cutoff of August 24, 2018, 107 patients had been enrolled
in the phase II portion. Before the phase II portion, six patients were
enrolled in a phase Ib safety run-in period. Three patients received one
prior line of therapy, and the remaining had two or more lines.
Although no responses were observed, two patients had SD (Supple-
mentary Table S1). Five of six patients had a treatment-related AE
(TRAE).
Fifty-two patients had received durvalumab in combination with
tremelimumab (27 second line and 25 third line), 24 had received
durvalumabmonotherapy, and 12 had received tremelimumabmono-
therapy. The median duration of follow-up was 9.2, 3.5, 9.2, and
10.7 months in arms A, B, C, and D, respectively. An additional 19
second- or later-line patients received durvalumab and tremelimumab
in the IFNg-high group. Baseline characteristics of patients in arms A
through E are shown in Table 1.
At the prespecified interim analysis, further enrollment in arms A,
B, and C was stopped at the sponsor's discretion despite meeting the
prespecified criteria for expansion, based on the evolving immuno-
therapy landscape in gastric cancer/GEJ cancer. The discontinuation
of enrollment in arms A, B, and C was not due to safety concerns.
Similarly, an interim analysis on data for 19 patients in armEalso led to
discontinuation of enrollment for that cohort.
Efficacy
No significant differences among the treatment arms were observed
in ORR and PFS (Table 2; Supplementary Fig. S2). The confirmed
ORR was 7.4% (two of 27 patients; 95% CI, 0.9%–24.3%) in arm A
compared with 0% in arm B (durvalumab monotherapy; 0 of 24
patients; 95% CI, 0%–14.2%) and 8.3% in arm C (tremelimumab
monotherapy; one of 12 patients; 95% CI, 0.2%–38.5%; Table 2;
Fig. 1). The PFS rate at 6 months was 6.1% (95% CI, 0.5%–22.2%),
0% (95% CI, NA), and 20.0% (95% CI, 3.1%–47.5%), respectively.
The median OS was 9.2 months (95% CI, 5.4–12.6 months),
3.4 months (95% CI, 1.7–4.4 months), and 7.7 months (95% CI,
2.1–13.7 months) in the combination therapy (arm A), durvalumab
monotherapy (arm B), and tremelimumab monotherapy (arm C)
arms, respectively (Fig. 2). The OS rate at 12 months in the combi-
nation therapy arm (arm A) was 37.0% (95% CI, 19.6%–54.6%)
compared with 4.6% (95% CI, 0.3%–19.0%) and 22.9% (95% CI,
3.5%–52.4%) in the durvalumab monotherapy and tremelimumab
monotherapy arms, respectively. The OS rate at 24 months was 18.5%
(95% CI, 6.7%–34.8%) in the combination therapy arm, 0% in the
durvalumab monotherapy arm, and 11.5% (95% CI, 0.6%–39.6%) in
the tremelimumab monotherapy arm.
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Table 1. Baseline characteristics.
Arm A Arm B Arm C Arm D Arm E
Characteristics 2L DþT 2L D 2L T 3L DþT 2L/3L DþT IFNgþ
No. of patients (n ¼ 27) (n ¼ 24) (n ¼ 12) (n ¼ 25) (n ¼ 19)
Median age (range), years 64.0 (27–78) 60.0 (29–79) 54.0 (19–74) 59.0 (35–75) 57.0 (32–82)
Male, n (%) 20 (74.1) 19 (79.2) 8 (66.7) 16 (64.0) 14 (73.7)
Race, n (%)a
Asian 7 (25.9) 11 (45.8) 5 (41.7) 12 (48.0) 13 (68.4)
Other 0 0 1 (8.3) 0 0
White 20 (74.1) 13 (54.2) 6 (50.0) 13 (52.0) 6 (31.6)
Extent of disease at study entry, n (%)b
Locoregionally recurrent only 2 (7.4) 1 (4.2) 2 (16.7) 0 0
Locoregionally recurrent with metastasis 14 (51.9) 14 (58.3) 2 (16.7) 13 (52.0) 9 (47.4)
Metastasis without locoregional recurrence 11 (40.7) 9 (37.5) 8 (66.7) 12 (48.0) 10 (52.6)
PD-L1 status, n (%)c
Highd 14 (51.9) 9 (37.5) 6 (50.0) 5 (20.0) 9 (47.4)
Low/negative 10 (37.0) 11 (45.8) 4 (33.3) 15 (60.0) 3 (15.8)
Unknowne 3 (11.1) 4 (16.7) 2 (16.7) 5 (20.0) 7 (36.8)
RMH score, n (%)f
0 15 (55.6) 5 (20.8) 6 (50.0) 11 (44.0) 5 (26.3)
1 6 (22.2) 4 (16.7) 3 (25.0) 9 (36.0) 7 (36.8)
2 6 (22.2) 15 (62.5) 3 (25.0) 4 (16.0) 5 (26.3)
3 0 0 0 0 2 (10.5)
Unknown 0 0 0 1 (4.0) 0
GRIm score, n (%)f
0 12 (44.4) 7 (29.2) 3 (25.0) 15 (60.0) 7 (36.8)
1 12 (44.4) 10 (41.7) 8 (66.7) 6 (24.0) 6 (31.6)
2 1 (3.7) 4 (16.7) 1 (8.3) 2 (8.0) 5 (26.3)
3 0 2 (8.3) 0 1 (4.0) 1 (5.3)
Unknown 2 (7.4) 1 (4.2) 0 1 (4.0) 0
aEach race category counts patients who selected only that category.
bInformation is missing for one patient in arm B.
cPD-L1 expression was determined using the VENTANA SP263 assay.
dPD-L1 high was defined as 1% tumor cells at baseline.
ePD-L1 unknown was defined as percentage of tumor cells not available at baseline.
fRMH or GRIm score of 2 or 3 was classified as a high score.
Table 2. Efficacy endpoints.
Arm A Arm B Arm C Arm D Arm E
2L DþT 2L D 2L T 3L DþT 2L/3L DþT IFNgþ
Endpoint (n ¼ 27) (n ¼ 24) (n ¼ 12) (n ¼ 25) (n ¼ 19)
ORR, n (%; 95% CI) 2 (7.4; 0.9–24.3) 0 (0; 0–14.2) 1 (8.3; 0.2–38.5) 1 (4.0; 0.1–20.4) 3 (15.8; 3.4–39.6)
Complete response 0 0 0 0 1 (5.3)
Partial response 2 (7.4) 0 1 (8.3) 1 (4.0) 2 (10.5)
Stable disease 5 (18.5) 3 (12.5) 2 (16.7) 6 (24.0) 1 (5.3)
Progressive disease 15 (55.6) 14 (58.3) 5 (41.7) 14 (56.0) 12 (63.2)
Nonevaluablea 5 (18.5) 7 (29.2) 4 (33.3) 4 (16.0) 3 (15.8)
Ongoing response rate 2 (100) NA 0 0 1 (33.3)
DCR, n (%; 95% CI) 7 (25.9; 11.1–46.3) 3 (12.5; 2.7–32.4) 3 (25.0; 5.5–57.2) 7 (28.0; 12.1–49.4) 4 (21.1; 6.1–45.6)
DCR24, n (%; 95% CI) 2 (7.4; 0.9–24.3) 0 (0; 0–14.2) 3 (25.0; 5.5–57.2) 3 (12.0; 2.5–31.2) 3 (15.8; 3.4–39.6)
Median time to response, weeks (95% CI) 16.1 (8.1–24.0) NA 11.6 (NA–NA) 31.1 (NA–NA) 7.7 (7.3–8.0)
Median duration of response (95% CI), weeks NA NA 20.1 (NA–NA) 32.3 (NA–NA) 13.3 (8.1–NA)
Median PFS (95% CI), months 1.8 (1.6–3.3) 1.6 (1.0–1.8) 1.7 (0.8–5.3) 1.8 (1.6–3.5) 1.8 (1.6–1.9)
PFS-6 (95% CI), % 6.1 (0.5–22.2) NA 20.0 (3.1–47.5) 15.0 (4.0–32.6) NA
Median OS (95% CI), months 9.2 (5.4–12.6) 3.4 (1.7–4.4) 7.7 (2.1–13.7) 10.6 (4.8–14.8) 7.0 (2.4–7.5)
OS-12 (95% CI), % 37.0 (19.6–54.6) 4.6 (0.3–19.0) 22.9 (3.5–52.4) 38.8 (19.2–58.1) NA
OS-24 (95% CI), % 18.5 (6.7–34.8) 0 (0–0) 11.5 (0.6–39.6) 9.7 (1.7–26.5) NA
Abbreviations: 2L, received treatment in the second-line setting; 3L, received treatment in the third-line setting; D, durvalumab; DCR, disease control rate (complete
response þ partial response þ stable disease); DCR24, DCR at 24 weeks (complete response þ partial response þ stable disease 24 weeks); NA, not applicable;
OS-12, OS rate at 12 months; OS-24, OS rate at 24 months; T, tremelimumab.
aNonevaluable includespatientswith only abaseline assessment or a responseof complete response, partial response, or stable disease at an interval of<54days (the
minimumcriteria for stable disease duration)without subsequent disease evaluation andpatientswho hadall overall response evaluations assessed as nonevaluable.
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In armD, in which 25 third-line patients were enrolled and received
combination durvalumab and tremelimumab, the observed ORR was
4.0% (1 of 25 patients; 95% CI, 0.1%–20.4%) and median OS was
9.2 months (95% CI, 5.4–12.6 months). The PFS rate at 6 months was
15.0% (95% CI, 4.0%–32.6%). The OS rates at 12 and 24 months were
38.8% (95% CI, 19.2%–58.1%) and 9.7% (95% CI, 1.7%–26.5%),
respectively.
In arm E, 176 patients had tumor samples submitted for prescreen-
ing; 27 were ultimately screened. Nineteen patients were enrolled, with
a median follow-up duration of 5.8 months. Among the samples
prescreened for potential enrollment, the IFNg gene signature assay
had a 70% success rate. The primary reason for failure was insufficient
tissue resulting in insufficient nucleic acid available for RNA sequenc-
ing. The distribution of patients observed in the cohort was as
Figure 1.
Three-dimensional waterfall and swimplots of armA (A), armB (B), armC (C), armD (D), and arm E (E). The x-axis depicts individual patients; the y-axis depicts best
change frombaseline (%). CR, PD, SD, PR, and SDwere all per RECIST 1.1. Blue dot represents new lesion. The z-axis represents duration of treatment (weeks); red dot,
ongoing therapy. White dot, baseline tumor size (mm); NE, not evaluable.
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expected, with 37.5% of prescreened patients having an elevated
signature and 62.5% not having elevated expression. There was one
CR (5%), two confirmed PRs (10.5%), and one patient (5%) with SD;
the ORR was 15.8% (3 of 19 patients; 95% CI, 3.4%–39.6%). Duration
of response was 13.3 weeks (range, 8.1–16.3 weeks). Median PFS was
1.8 months (95% CI, 1.6–1.9 months), PFS rate at 6 months was 0%
(95% CI, NA), and median OS was 7.0 months (95% CI, 2.4–
7.5months).We correlated the degree of IFNg gene signature intensity
with best overall response (Supplementary Fig. S3). Interestingly, in
patients achieving CR or PR (n ¼ 3), there was no difference in IFNg
intensity (2.84 vs. 2.83; P ¼ 0.99) compared with those who had
progressive disease (PD; n ¼ 14).
Prognostic scores
RMH and GRiM prognostic scores were retrospectively evaluated
for all treatment arms. The proportion of those with low RMH
scores (0–1 vs. >1) was 77.8%, 37.5%, 75.0%, 80.0%, and 63.2% for
arms A through E, respectively, indicating that more patients
enrolled in arms B and E were likely to have a poorer prognosis
than patients in the other treatment arms. A lower percentage of low
GRiM scores (0–1 vs. >1) was observed in arms B and E than in
other treatment arms (92.6%, 70.8%, 91.7%, 84.0%, and 68.4%,
respectively), which may explain in part the decreased OS rates
observed in these patients.
Biomarker evaluations
MSI status was obtained for patients in all study cohorts (A–E),
characterized using whole-exome sequencing (MSIsensor; ref. 25). A
cutoff score of10 was used to defineMSI-high (MSI-H; ref. 26). One
patient in arm C was MSI-H (score 13) and was a nonresponder. All
other patients (n¼ 72) weremicrosatellite stable (Fig. 3). PD-L1 status
was available for 80.4% of patients (86/107). Clinical activity regarding
PFS and OS was not affected by PD-L1 status (Supplementary
Table S2). Furthermore, tumor mutation burden (TMB) was calcu-
lated using whole-exome sequencing. Median TMB in arms A–D was
2.13mutations per megabase (Mb). There was no correlation with PFS
or OS when comparing high versus low TMB based on median, upper
tertile, and upper quartile cutoff points. In addition, no differences
were observed on the basis of response status (Supplementary Fig. S4).




MSI status based on responder status by arm. Data based on MSIsensor, which uses whole-exome sequencing for characterization of MSI status. Cut-off value 10
designates MSI-H. Red dots, responders (R); blue dots, nonresponders (NR).
Durvalumab and Tremelimumab in Gastric and GEJ Adenocarcinoma
AACRJournals.org Clin Cancer Res; 26(4) February 15, 2020 851
on April 6, 2020. © 2020 American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from 
Published OnlineFirst November 1, 2019; DOI: 10.1158/1078-0432.CCR-19-2443 
n ¼ 11). Similar to other arms, there was no correlation of TMB with
response status.
ctDNA samples were obtained from 72 patients at baseline and 31
patients at both baseline and 9 weeks on treatment. Patients with PR
showed a decrease (D, 10.05%; P ¼ 0.26) in VAF posttreatment,
compared with a significant increase in mean VAF in patients with
PD (D, þ8.14%; P ¼ 0.03; Supplementary Fig. S5). This correlation
was also observed in total mutation count in patients with PR (D,6.7;
P¼ 0.17) comparedwith patients with PD (D,þ2.2; P¼ 0.06). Patients
with a decrease in VAF at week 9 had longer median PFS [5.4 months;
95% CI, 3.7–not reached (NR; ref. 27) and OS (median, 13.8 months;
95% CI, 7.0–NR) than those with an increase in VAF [median PFS,
1.9 months (95% CI, 1.8–NR); HR, 0.33; 95% CI, 0.09–1.21] and
median OS, 8.2 months (95% CI, 6.2–NR); HR, 0.07; 95% CI, 0.01–
0.66]. In addition, by using ctDNA, KRASmutation (nonsynonymous
single variant nucleotide) was identified in 2 of 113 patients (1.8%),
both of whom had PD.
Safety and tolerability
In the phase Ib portion, one of six patients had a dose-limiting
toxicity of grade 3 hepatic function abnormality (transaminitis), which
was initially attributed as possibly related to the investigational drug;
further evaluation revealed that the patient had disease progression of
liver metastases. The dose of 20 mg/kg durvalumab and 1 mg/kg
tremelimumab was confirmed safe and tolerable for the phase II
portion.
In the phase II part of this study, the proportion of patients reporting
one or more TRAE was 33.3% in the durvalumab monotherapy arm
and 66.7% in the tremelimumab monotherapy arm. The incidence of
AEs varied between the combination treatment arms (A, 70.4%; D,
56.0%; E, 42.1%). The most frequently observed TRAEs (10% any
grade in any treatment arm) included fatigue, diarrhea, decreased
appetite, and pruritus (Table 3). TRAEs leading to treatment discon-
tinuation occurred in 14.8% (4/27), 20.0% (5/25), and 5.3% (1/19) in
the three combination therapy arms (arms A, D, and E), compared
with 33.3% of patients (4/12) in the tremelimumab monotherapy arm
and 4.2% of patients (1/24) in the durvalumab monotherapy arm. No
TRAEs leading to death were observed.
Discussion
This completed phase Ib/II study is the first to evaluate a PD-L1 and
CTLA-4 combination strategy in metastatic gastric cancer/GEJ ade-
nocarcinoma and shows that the combination of durvalumab and
tremelimumab demonstrated numerically higher rates of confirmed
response than durvalumab monotherapy. Twelve-month OS rates in
the combined therapy arms were comparable with the combination
of nivolumab with ipilimumab in the CheckMate 032 study (37% vs.
35%; ref. 6). As anticipated, the incidence of TRAEs was higher in the
combination arm and the tremelimumab monotherapy arm than in
the durvalumab monotherapy arm.
In this study, we prospectively screened patients with a novel
RNA-based IFNg gene expression signature comprising IFNg, CD274,
LAG3, and CXCL9. We found this approach to be feasible for patient
selectionwith predictable assay performance. Although theORRswith
durvalumab and tremelimumab were higher in the IFNg signature-
high group than those in unselected populations, survival outcomes
remained similar. One important distinction between the assessment
of the IFNg gene signature in this study and that used in previous
studies (15) was the use of archival tissue rather than fresh tissue. We
postulate that IFNg is a dynamic marker and scores can vary based on
multiple factors, including timing of tissue acquisition, number of
previous lines of therapy, and location of tissue acquisition (primary
tumor vs. metastatic site). In this study, archival tissue was used due to
availability and for pragmatic reasons to prevent delay in initiation of
therapy in this fragile patient population. Given the added complexity
of patient preselection and lack of substantial improvement in
clinical outcomes, these results do not support further implementation
Table 3. Treatment-related AEs, 10% any grade in any arm.
Arms A þ D þ E Arm B Arm C
2L/3L DþT 2L D 2L T
(n ¼ 71) (n ¼ 24) (n ¼ 12)
Adverse event Any Grade Grade 3/4 Any Grade Grade 3/4 Any Grade Grade 3/4
Diarrhea 12 (16.9) 2 (2.8) 1 (4.2) 0 3 (25.0) 1 (8.3)
Aspartate aminotransferase increased 2 (2.8) 0 0 0 3 (25.0) 1 (8.3)
Dyspnea 4 (5.6) 0 0 0 3 (25.0) 0
Fatigue 14 (19.7) 2 (2.8) 2 (8.3) 0 2 (16.7) 1 (8.3)
Decreased appetite 11 (15.5) 1 (1.4) 3 (12.5) 0 1 (8.3) 0
Colitis 4 (5.6) 3 (4.2) 0 0 2 (16.7) 2 (16.7)
Pruritus 8 (11.3) 0 0 0 2 (16.7) 0
Rasha 9 (12.7) 1 (1.4) 0 0 2 (16.7) 0
Alanine aminotransferase increased 1 (1.4) 1 (1.4) 0 0 2 (16.7) 0
Lipase increased 2 (2.8) 2 (2.8) 0 0 2 (16.7) 1 (8.3)
Dermatitis acneiform 1 (1.4) 0 0 0 2 (16.7) 1 (8.3)
Nausea 6 (8.5) 1 (1.4) 1 (4.2) 0 1 (8.3) 0
Dry skin 2 (2.8) 0 0 0 2 (16.7) 0
Amylase increased 2 (2.8) 2 (2.8) 0 0 2 (16.7) 0
Vomiting 4 (5.6) 0 0 0 1 (8.3) 0
Weight decreased 4 (5.6) 0 0 0 0 0
Hyperglycemia 3 (4.2) 2 (2.8) 0 0 0 0
Blood thyroid-stimulating hormone increased 3 (5.8) 0 0 0 0 0
Hypothyroidism 3 (5.8) 0 0 0 0 0
aPooled data for rash and rash maculopapular.
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of the IFNg gene signature for patient selection, as designed, in this
population.
The use of PD-L1 expression as a biomarker for patient selection in
advanced gastric cancer/GEJ cancer continues to evolve. In studies of
pembrolizumab, PD-L1 status was assessed using the combined
positive score (CPS), which counts PD-L1 staining in both tumor
and peritumoral mononuclear cells (5). With the CPS, PD-L1–
negative (CPS 0) tumors are associated with worse outcomes than
PD-L1–positive tumors (CPS1). These findings are consistent with a
recent meta-analysis, suggesting that PD-L1 expression levels are
associated with OS (28). However, in the current study, no clear
difference in clinical activity based on PD-L1 status was observed.
Thismay be explained by our use of PD-L1 staining in tumor cells only,
as well as differences in patient cohorts and immunohistochemistry
antibodies.
To validate additional biomarkers, we evaluated pretreatment and
on-treatment levels of ctDNA in a subset of patients in this study.
Although our sample size was small, ctDNA VAFs were consistently
reduced after 9 weeks of therapy in responders but not in non-
responders. A decrease in VAF following 9 weeks of treatment
correlated with longer PFS and OS, suggesting utility as an early
indicator of clinical benefit (Supplementary Fig. S5). These findings
have also been observed independently in other cancers and suggest
that ctDNA may be a promising biomarker of response to ICIs in
gastric cancer. Importantly, the utilization of ctDNA VAF changes
should be evaluated in future studies as a method of determining
response to treatment rather than relying solely on radiographic
changes as measured by the RECIST criteria. This is particularly
because clinical responses may be delayed and can infrequently be
preceded by apparent progression (so-called pseudoprogression).
One possibility for the differences in efficacy observed in arm B
(durvalumab monotherapy) and arm E (IFNg signature–high, durva-
lumab plus tremelimumab) compared with the other study arms may
be a higher rate of enrolled patients with poor prognostic factors, as
measured by RMH and GRIm scores. In a separate phase I trial,
durvalumab monotherapy demonstrated a higher rate of OS in
patients with eligibility characteristics similar to those in this
study (17). The possibility that patients with more adverse features
were enrolled in this study is supported by the observation that only 1
of 72 evaluated patients (1.4%) had an MSI-high tumor; this is lower
than the 4% incidence normally noted in patients with metastatic
disease and the 12% of patients (7/59) treated with nivolumab alone in
CheckMate 032 (6).
A limitation of this study is the relatively small sample size in each
cohort, which affected the statistical power and precluded the ability to
distinguish between treatment arms. Per protocol, enrollment was
stopped following interim analyses of efficacy. In addition, although
pembrolizumabwas active in patients whowereMSI-H and those with
EBV-associated gastric cancer/GEJ cancer (29), we are unable to
conclude how the therapies in our study would perform in these
specific populations. As mentioned above, there was a very low
proportion of MSI-H patients. EBV status was not available, as testing
viral status was not a standard practice at the time of this trial.
Furthermore, a lack of available tissue precluded EBV testing
retrospectively.
In summary, this is the second trial to investigate the efficacy of
combination checkpoint inhibitors in gastric cancer/GEJ cancer and
the first to assess a PD-L1 inhibitor with a CTLA-4 inhibitor. Although
responses rates with durvalumab or tremelimumabmonotherapy or in
combination were low, the combination approach resulted in a 12-
month OS rate of approximately 37%. These results highlight that a
better understanding of the underlying immune microenvironment is
paramount to prospectively identify which patients should receive
combined checkpoint inhibitors. Biomarker strategies beyond PD-L1
expression,MSI status, and the use of IFN gene expression are ongoing.
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